Pink Sheet reports on Aranesp and Procrit concerns

Share this article:
Members of the FDA's Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen's Aranesp and Johnson & Johnson's Procrit have given patients a lopsided impression of the drugs' risk/benefit profile, The Pink Sheet reported. The state of New York subpoenaed Aranesp promotional materials that month.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.